In the Claims:

The current status of all claims is listed below and supercedes all previous lists of claims.

Please cancel claims 10, 12, and 14 without prejudice to their presentation in another application, amend claims 1-5, 7, 11, 13, and 15-17, and add new claim 18 as follows.

1. (currently amended) A compound of formula I



I

wherein

R^1 represents a) a C_{1-4} alkoxy group optionally substituted by one or more fluoro, b) a C_{1-4} alkyl group optionally substituted by one or more fluoro, c) halo, d) cyano, e) a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O ~~atom~~ atom, f) a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring, or g) a group $-OSO_2C_{1-4}$alkyl optionally substituted by one or more fluoro;

n represents 0, 1, 2 or 3;

R^2 represents H or cyano or a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

R^3 represents H or a C_{1-4} alkyl group;

L^1 represents a $(CH_2)_pC_{3-10}$ cycloalkyl group in which p is 0 or 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R^3 and R^4, respectively, are not linked to the same carbon atom, and wherein one of the carbons may be replaced by O; with the proviso that L^1 does not represent 1,3-cyclopentyl or 1,4-cyclohexyl;

R^4 represents H or a C_{1-4} alkyl group optionally substituted by one or more of the following: fluoro or C_{1-4} alkoxy optionally substituted by one or more fluoro;

L^2 represents an alkylene chain $(CH_2)_s$ in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: fluoro or C_{1-4} alkyl;

L^2 may also represent a 5-6 membered carbocyclic 5-6 membered ring fused to R^5;

R^5 represents phenyl or naphthyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl, benzo[*b*]thienyl, imidazolyl, benzimidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-*a*]pyridinyl, 5*H*-pyrrolo[2,3-*b*]pyrazinyl, 1*H*-pyrrolo[3,2-*c*]pyridinyl, 1*H*-pyrrolo[2,3-*c*]pyridinyl, 1*H*-pyrrolo[2,3-*b*]pyridinyl, *1H*-indazolyl, wherein each R^5 is optionally substituted by one or more of the following: a) cyano, b) halo, c) a C_{1-4} alkyl group optionally substituted by one or more fluoro, d) a C_{1-4} alkoxy group optionally substituted by one or more fluoro, e) a group $S(O)_aR^y$ in which a is 0, 1 or 2 and R^y is phenyl optionally substituted by cyano, halo, a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, f) or by a group $(CH_2)_zR^z$ in which z and w is 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, or a C_{1-4}alkoxy group optionally substituted by one or more fluoro;

as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof.

2. (currently amended) A compound as claimed in claim1 in which

R^1 represents cyano or a C_{1-4} alkoxy group optionally substituted by one or more fluoro,

a C_{1-4} alkyl group optionally substituted by one or more fluoro, halo, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ~~ring~~, ring;

n represents 0, 1, 2 or 3;

R^2 represents H or cyano or a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

R^3 represents H or a C_{1-4} alkyl group;

L^1 represents a $(CH_2)_pC_{5-6}$ cycloalkyl group in which p is 0 or 1 and provided that there are 3 carbon atoms between the two nitrogens bearing R^3 and R^4, respectively, wherein one of the carbons of the cycloalkyl group may be replaced by O;

R^4 represents H or a C_{1-4} alkyl group optionally substituted by one or more of the following: fluoro or C_{1-4} alkoxy optionally substituted by fluoro;

L^2 represents an alkylene chain $(CH_2)_s$ in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: fluoro or C_{1-4} alkyl;

L^2 may also represent a 5-6 membered carbocyclic 5-6 membered ring fused to R^5;

R^5 represents aryl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl, benzo[*b*]thienyl, imidazolyl, benzimidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-*a*]pyridine, 5*H*-pyrrolo[2,3-*b*]pyrazine, 1*H*-pyrrolo[3,2-*c*]pyridine, 1*H*-pyrrolo[2,3-*c*]pyridine, 1*H*-pyrrolo[2,3-*b*]pyridine, *1H*-indazole each of which is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or a group $(CH_2)_zR^z$ in which z is 0 or 1 and R^z

represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4}alkoxy group optionally substituted by one or more fluoro or by a group $S(O)_aR^y$ in which a is 0, 1 or 2 and R^y is phenyl optionally substituted by cyano, halo, a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more ~~fluoro,~~ fluoro;

as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof.

3. (currently amended) A compound ~~according to claim 1 or claim 2~~ of formula IA



IA

in which

R^1 represents chloro, fluoro, methoxy or a group NR^aR^b in which R^a and R^b independently represent a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O;

n represents 0 or 1, and when n=1 the substituent is attached to either position 6 ~~or 7~~ or 7;

R^2 represents H or cyano or a C_{1-4}alkyl group, a C_{1-4}alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic

ring;

~~m represents 0 or 1;~~

R^3 represents H;

A represents CH_2 and t is 1;

R^4 represents H;

L^2 represents CH_2, $C(CH_3)_2$ or CF_2; and

R^5 represents aryl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl, benzo[*b*]thienyl, imidazolyl, benzimidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-*a*]pyridine, 5*H*-pyrrolo[2,3-*b*]pyrazine, 1*H*-pyrrolo[3,2-*c*]pyridine, 1*H*-pyrrolo[2,3-*c*]pyridine, 1*H*-pyrrolo[2,3-*b*]pyridine, *1H*-indazole each of which is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a group $S(O)_nR^y$ in which a is 0, 1 or 2 and R^y is phenyl optionally substituted by cyano, halo, a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, or a group $(CH_2)_zR^z$ in which z is 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4}alkoxy group optionally substituted by one or more ~~fluoro~~ fluoro;

as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts thereof.

4. (currently amended) A compound ~~according to any previous claim~~ of formula IB



IB

in which

R^1 represents H, cyano, methoxy, isopropoxy, dimethylamino, chloro or fluoro;

R^2 represents H, cyano, a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including ~~an O,~~ an O;

R^3 represents H;

A represents CH_2 and t is 1;

R^4 represents H;

L^2 represents CH_2, $C(CH_3)_2$ or CF_2; and

R^5 represents aryl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl, benzo[*b*]thienyl, imidazolyl, benzimidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-*a*]pyridine, 5*H*-pyrrolo[2,3-*b*]pyrazine, 1*H*-pyrrolo[3,2-*c*]pyridine, 1*H*-pyrrolo[2,3-*c*]pyridine, 1*H*-pyrrolo[2,3-*b*]pyridine, *1H*-indazole each of which is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a group $S(O)_aR^y$ in which a is 0, 1 or 2 and R^y is phenyl optionally substituted by cyano, halo, a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, or a group $(CH_2)_zR^z$ in which z is 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4}alkoxy group optionally substituted by one or more ~~fluoro~~ fluoro;

as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts thereof.

5. (currently amended) A compound ~~as claimed in claim 1~~ as represented by formula IC



IC

in which

R^1 represents cyano or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a C_{1-4} alkyl group optionally substituted by one or more fluoro, halo, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ~~ring,~~ ring;

n represents 0, 1, 2 or 3;

R^2 represents H, cyano, a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

R^3 represents H or a C_{1-4} alkyl group;

L^1 represents a $(CH_2)_pC_{7-10}$ cycloalkyl group in which p is 0 or 1 and in which the cycloalkyl group is fused bicyclic or bridged bicyclic provided that the two nitrogens bearing R^3 and R^4, respectively, are not linked to the same carbon atom, and wherein one of the carbons may be replaced by O;

R^4 represents H or a C_{1-4} alkyl group optionally substituted by one or more of the following: fluoro or C_{1-4} alkoxy, optionally substituted by one or more fluoro;

L^2 represents an alkylene chain $(CH_2)_s$ in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: fluoro or C_{1-4} alkyl;

or L^2 may also represent a 5-6 membered carbocyclic ring fused ~~to R^5;~~ to R^5;

R^5 represents aryl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl, benzo[*b*]thienyl, imidazolyl, benzimidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-*a*]pyridine, 5*H*-pyrrolo[2,3-*b*]pyrazine, 1*H*-pyrrolo[3,2-*c*]pyridine, 1*H*-pyrrolo[2,3-*c*]pyridine, 1*H*-pyrrolo[2,3-*b*]pyridine, *1H*-indazole each of which is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a group $S(O)_aR^y$ in which a is 0, 1 or 2 and R^y is phenyl optionally substituted by cyano, halo, a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, or a group $(CH_2)_zR^z$ in which z is 0 or and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4}alkoxy group optionally substituted by one or more ~~fluoro~~ fluoro;

as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts thereof ~~thereof.~~.

6. (original) A compound as claimed in any one of claims 1 to 4 in which p is 0 and L^1 is 1,3-cyclohexyl.

7. (currently amended) A compound as claimed in any one of claims ~~1 to 6~~ 1 to 5 in which the two nitrogen atoms are in a trans orientation on the cycloalkyl ring.

8. (original) A compound as claimed in claim 7 wherein the stereochemistry of the cycloalkyl carbon atoms to which the nitrogen atoms are attached is S, S.

9. (original) One or more of the following compounds:

N-(4-methylquinazolin-2-yl)-*N'*-(3-thienylmethyl)-*trans*- cyclohexane-1,3-diamine;

N^4,N^4-dimethyl-N^2-{-3-[(3-thienylmethyl)amino]-*trans*-cyclohexyl}quinazoline-2,4-diamine;

N^2-{-3-[(1-benzothien-3-ylmethyl)amino]-*trans*-cyclohexyl}-N^4,N^4-dimethylquinazoline-2,4-diamine;

N^4,N^4-dimethyl-N^2-(-3-{[(1-methyl-1*H*-indol-3-yl)methyl]amino}-*trans*-cyclohexyl)quinazoline-2,4-diamine,

N^4, N^4-dimethyl-N^2 -((1S,3S)-3-{[2-(trifluoromethoxy)benzyl]amino}cyclohexyl)-quinazoline-2,4-diamine;

N^4, N^4-dimethyl-N^2 -[(1S,3S)-3-({[6-(trifluoromethyl)pyridin-3-yl]methyl}amino)-cyclohexyl]quinazoline-2,4-diamine; and

N^{2}-{(1S,3S)-3-[(3,4-dichlorobenzyl)amino]cyclohexyl}-N^4-N^4-dimethylquinazoline-2,4-diamine;

and pharmaceutically acceptable salts thereof.

10. (canceled).

11. (currently amended) A pharmaceutical formulation comprising a compound of formula I, as defined in any one of claims ~~1 to 9~~ 1 to 5 or in claim 9 and a pharmaceutically acceptable adjuvant, diluent or carrier.

12. (canceled).

13. (currently amended) A method of treating obesity, a psychiatric disorder ~~psychiatric disorders~~, anxiety, an anxio-depressive disorder ~~anxio-depressive disorders~~, depression, bipolar disorder, ADHD, a cognitive disorder ~~cognitive disorders~~, a memory disorder ~~memory disorders~~, schizophrenia, epilepsy, ~~and related conditions, and~~ a neurological disorder, ~~neurological disorders and~~ or a pain related disorder ~~pain related disorders~~, comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims ~~1 to 9~~ 1 to 5 or in claim 9 to a patient in need thereof.

14. (canceled).

15. (currently amended) A process for the preparation of a compound ~~compounds~~ of formula I ~~as claimed in claim 1~~



I

comprising reacting a compound of formula



II

in which ~~R^1, R^2, R^3, R^4, L^1, n and m are as previously defined in claim 1~~

R^1 represents a) a C_{1-4}alkoxy group optionally substituted by one or more fluoro, b) a C_{1-4}alkyl group optionally substituted by one or more fluoro, c) halo, d) cyano, e) a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O atom, f) a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring, or g) a group $-OSO_2C_{1-4}$alkyl optionally substituted by one or more fluoro;

R^2 represents H or cyano or a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring

optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

R^3 represents H or a C_{1-4} alkyl group;

R^4 represents H or a C_{1-4} alkyl group optionally substituted by one or more of the following: fluoro or C_{1-4}alkoxy optionally substituted by one or more fluoro;

L^1 represents a $(CH_2)_pC_{3-10}$ cycloalkyl group in which p is 0 or 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R^3 and R^4, respectively, are not linked to the same carbon atom, and wherein one of the carbons may be replaced by O; with the proviso that L^1 does not represent 1,3-cyclopentyl or 1,4-cyclohexyl; and

n represents 0, 1, 2 or 3;

with a compound of formula III

III

in which ~~R^5 is as previously defined and~~

R^5 represents phenyl or naphthyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl, benzo[*b*]thienyl, imidazolyl, benzimidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-*a*]pyridinyl, 5*H*-pyrrolo[2,3-*b*]pyrazinyl, 1*H*-pyrrolo[3,2-*c*]pyridinyl, 1*H*-pyrrolo[2,3-*c*]pyridinyl, 1*H*-pyrrolo[2,3-*b*]pyridinyl, *1H*-indazolyl, wherein each R^5 is optionally substituted by one or more of the following: a) cyano, b) halo, c) a C_{1-4}alkyl group optionally substituted by one or more fluoro, d) a C_{1-4}alkoxy group optionally substituted by one or more fluoro, e) a group $S(O)_aR^y$ in which a is 0, 1 or 2 and R^y is phenyl optionally substituted by cyano, halo, a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, f) or by a group $(CH_2)_zR^z$ in which z and w is 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, or a C_{1-4}alkoxy group optionally substituted by one or more

fluoro; and

$L^{2'}$ represents a group which after reaction of compounds II and III gives L^2 on reduction, under reductive alkylation conditions.

16. (currently amended) ~~Intermediates~~ A compound of formula II



II

in which ~~R^1, R^2, R^3, R^4, L^1, n and m are as defined in claim 1~~

R^1 represents a) a C_{1-4} alkoxy group optionally substituted by one or more fluoro, b) a C_{1-4} alkyl group optionally substituted by one or more fluoro, c) halo, d) cyano, e) a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O atom, f) a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring, or g) a group $-OSO_2C_{1-4}$alkyl optionally substituted by one or more fluoro;

R^2 represents H or cyano or a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

R^3 represents H or a C_{1-4} alkyl group;

R^4 represents H or a C_{1-4} alkyl group optionally substituted by one or more of the following: fluoro or C_{1-4} alkoxy optionally substituted by one or more fluoro;

L^1 represents a $(CH_2)_pC_{3-10}$ cycloalkyl group in which p is 0 or 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R^3 and R^4, respectively, are not linked to the same carbon atom, and wherein one of the carbons may be replaced by O; with the proviso that L^1 does not represent 1,3-cyclopentyl or 1,4-cyclohexyl; and

n represents 0, 1, 2 or 3.

17. (currently amended) A method of treating obesity, type II diabetes, or Metabolic syndrome ~~and prevention of type II diabetes~~ comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims ~~1 to 9~~ 1 to 5 or in claim 9 to a patient in need thereof.

18. (new) A method of preventing type II diabetes comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 5 or in claim 9 to a patient in need thereof.